Bristol-Myers Squibb Co. reported a 76 percent increase in the fourth-quarter profit Thursday, driven in part by sales of a recently-approved diabetes drug and hefty charges a year earlier, though the drugmaker still fell short of Wall Street's expectations.

MARSEILLE, France (Reuters) - Jean-Claude Mas, the Frenchman who has sparked a global health scare by selling substandard breast implants, was arrested on Thursday and could be charged with manslaughter, the public prosecutor in the city of Marseille said.

[Business Wire] - Celgene Corporation reported Non-GAAP net product sales of $1,241 million for the fourth quarter of 2011, a 21 percent increase from the same period in 2010. Non-GAAP net income for the fourth quarter of 2011 increased 38 percent to $473 million compared to $343 million in the fourth quarter of 2010.

GSK accused of RLS drug contract breach by Xenoport

Generic drug manufacturer agrees to remedy deviations from the current good manufacturing practice requirements and to correct data integrity problems at numerous facilities SILVER SPRING, Md., Jan. 25, 2012 /PRNewswire-USNewswire/ -- The Department of Justice, on behalf of...

Here is a case where the glass is either half full or half empty. A new survey finds that 51 percent of adults in the US access some type of information about medicines and health issues on a web site or mobile app that is sponsored by a drugmaker. Among the topics being explored: info about specific conditions, disease management and treatment, and guides for having discussions with doctors.

You can get all sorts of things when you pay $2.9 billion for a biotech, including an admonition from the FDA. That's what happened to Celgene last month, when the FDA issued a stern letter for a troublesome white paper that Abraxis BioScience had distributed at the American Society of Clinical Oncology meeting nearly two years ago. The subject of the white paper was Abraxene, an injectable med used to treat metastatic breast cancer and a key reason that Celgene bought the biotech in late 2010. However, the paper broadened the indication for Abraxane, made unsubstantiated effectiveness and superiority claims, and omitted and minimized important risk information associated with its use. As a result, misbranding occurred. There were other problems.

Good morning, everyone, and how are you today? As usual, we are scurrying about in hopes of delivering the short people to their various schoolhouses. So far, so good. Nonetheless, there is much to do. So, while we quaffe a cup or two of delicious stimulation - we are back to Southern Pecan - please enjoy the items we have assembled below. We hope these get you off to a good start. Meanwhile, have a great day and keep in touch... Amgen To Aquire Micromet For $1.2 Billion (Bloomberg News) Studies Reignite Debate Over Avastin For Breast Cancer (MedPage Today) Illumina Plans Poison Pill To Thwart Roche Bid (Bloomberg News) Celgene Buys Avila Therapeutics For $350 Million (Xconomy) Hepatitis A Vaccine Rates In The US Vary Widely (Reuters) The Effient Launch Was Worse That It Looked (RPM Report) West Virginia Bill Pushes Rx-Only Status For Pseudoephedrine (Charleston Daily Mail) EU May Force API Suppliers To Verify Starting Materials (InPharma Technologist) Covance Shocks Wall Street With IT Investment Plan (Outsourcing Pharma) EDITOR'S NOTE: Please check this post for updates throughout the morning

Licensing deals down as pharma tightens belt

Gilead tops table for antivirals

Charles River microsite looks for that Eureka moment

VC giant sees opportunities in Europe, invests in Netherlands' Prosensa

COPENHAGEN, Denmark, January 26, 2012 /PRNewswire/ -- LEO Pharma today announced that Picato® (ingenol mebutate) gel (0.015%, 0.05%) has been approved by the US Food and Drug Administration (FDA) as a treatment for actinic keratoses (AK) on the face, scalp, trunk and extremities....

Filing false data with the FDA can cause problems. Just ask Ranbaxy Laboratories, which last month agreed to pay a $500 million fine and accept a consent decree for a raft of manufacturing violations (back story). Now, the US Department of Justice has released more details - the feds have filed a consent decree for a permanent injunction that prevents the Indian drugmaker from making meds for the US market until certain facilities meet US standards. In announcing the consent decree, the feds are calling the move unprecedented. "This action against Ranbaxy is groundbreaking in its international reach " it requires the company to make fundamental changes to its plants in both the United States and India,- Tony West, Assistant Attorney General for the Justice Department's Civil Division, says in a statement. 

Here is a twist on the old adage, 'If a tree falls in a forest and there is no one to hear it, does it still make a sound?' Seven months ago, Bristol-Myers Squibb changed the label on its Kenalog steroid shot, which is frequently administered in epidural injections, to alert physicians that the medication should not be used near the spine after there were reports that some patients died or became paralyzed. Meanwhile...

NORTHVALE, N.J., Jan. 26, 2012 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite") (OTCBB:ELTP) announced today that on January 23, 2012, the U.S. Food and Drug Administration approved the Company's supplemental application for the manufacturing and packaging of Hydromorphone Hydrochloride USP 8 mg. This approval will allow the Company to commence the commercial manufacturing and packaging of this product for its sales and marketing partner, which will distribute the product as part of a multi-product distribution agreement.

PHILADELPHIA, Jan. 26, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") today announced that ANMAT (Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica), the agency responsible for the national regulation of drugs, foods and medical technology in Argentina, has approved the sale and distribution of Alferon N Injection(r) (under the brand name "Naturaferon") in Argentina. In June 2010, Hemispherx agreed to provide GP Pharm an option to market Alferon N Injection(r), its FDA-approved natural interferon, in Argentina and other Latin America countries. In December 2010, GP Pharm exercised this right and in July 2011 GP Pharm submitted an application for approval to ANMAT. Alferon N Injection(r) (Interferon alfa-n3 (human leukocyte derived)) is already approved in the US for the treatment of refractory or recurring external condylomata acuminate (genital warts) in patients 18 years of age or older. A major multi-million dollar investment scale-up of Alferon N Injection(r) manufacturing is underway at Hemispherx's New Brunswick, NJ facility.

The US Food and Drug Administration (FDA) has approved UCB's Keppra (levetiracetam) tablets and oral solution for treating adults and children one month of age and older with epilepsy.

(Reuters) - Health regulators said drugmakers Celgene Corp and Novartis AG misrepresented their cancer drugs to doctors, overstating how well the medicines targeted tumors without having evidence to support it.

WASHINGTON (Reuters) - U.S. health regulators amended the prescribing label for Merck & Co's cholesterol-lowering drug Vytorin to show it prevents heart problems in patients with chronic kidney disease, but stopped short of approving its use for that purpose.

SICHUAN, China, Jan. 26, 2012 /PRNewswire-Asia/ -- China Health Resource, Inc. (OTCBB: CHRI.OB News), announced today that it has signed two new agreements for the sale of Gastrodia valued at 67.5 Million RMB or approximately $10.7 Million USD (Corrected*). The agreements are with...

BURLINGTON, Mass., Jan. 26, 2012 /PRNewswire/ -- Palomar Medical Technologies, Inc. (Nasdaq: PMTI), a leading researcher and developer of light-based systems for cosmetic treatments, will hold its quarterly conference call of its 2011 fourth quarter and year-end financial results on...

LAVAL, QUEBEC, CANADA (MARKET WIRE) ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic"or the "Company") announced today that it has received a $2.5 million purchase order under its ongoing supply agreement with Octapharma, a leading, Swiss based, independent global plasma fractionation company that specializes in human proteins. This purchase order further confirms the binding forecast received from Octapharma and is in addition to the $0.73 million order announced in October 2011. More than $3.0 million of shipments to Octapharma are expected during the first half of 2012.

SAN DIEGO, Jan. 26, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) today announced the pricing of an underwritten public offering of 8,600,000 shares of its common stock at a price to the public of $5.25 per share. The gross proceeds to Trius from this offering are expected to be approximately $45.2 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Trius. The offering is expected to close on or about January 31, 2012, subject to customary closing conditions.

BOISE, ID (MARKET WIRE) MWI Veterinary Supply, Inc. (NASDAQ: MWIV) announced today that the Company will release financial results for its fiscal year 2012 first quarter ended December 31, 2011 and update its business outlook for its fiscal year ending September 30, 2012 on Thursday, February 2, 2012. MWI will host a conference call the same day at 11:00 am eastern time to discuss these results and its business outlook.

PHILADELPHIA and LONDON, Jan. 26, 2012 /PRNewswire/ -- The IP & Science business of Thomson Reuters today announced an agreement with Brazil's Institute for Applied Economic Research (IPEA). This partnership provides IPEA's Direction of Sectorial Studies and Policies for...

[at Forbes] - Today Celgene announced the acquisition of Avila Therapeutics for $350M upfront and up to $575M in future milestones. Congratulations to the Avila team! For those of us involved in the story, we certainly think Celgene's got itself a great deal. Like many of the big exits in 2011, Avila is yet another [...]

[at theflyonthewall.com] - Affymetrix to buyback $95.5M of notes to resolve suit with Tang, Bloomberg says

LONDON, ONTARIO (MARKET WIRE) Stellar Pharmaceuticals Inc. (OTCQB: SLXCF)(OTCBB: SLXCF)(PINKSHEETS: SLXCF) ("Stellar" or "the Company"), today announced that it has received another patent from the U.S. Patent and Trademark Office (USPTO) for intellectual property central to one of the Company's lead products, Uracyst(R) (a sterile sodium chondroitin sulfate solution, 2%), which is used in the treatment of interstitial cystitis/painful bladder syndrome ("IC/PBS").

ST. PAUL, MN (MARKET WIRE) EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced financial results for the three months and full year ended December 31, 2011.

PALO ALTO, Calif., Jan. 26, 2012 /PRNewswire/ -- Varian Medical Systems (NYSE: VAR) today announced it has booked a $77 million order with Saudi Particle Therapy Centre LLC to equip a new proton therapy facility at the King Fahd Medical Center in Riyadh, Saudi Arabia....

UNION CITY, Calif., Jan. 17, 2012 /PRNewswire/ -- Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, has scheduled a conference call to discuss its financial results for the third quarter of fiscal year 2012, ended...

DAVOS, Switzerland (Reuters) - Microsoft chairman and philanthropist Bill Gates pledged a further $750 million to the troubled global AIDS fund on Thursday and urged governments to continue their support to save lives.

PRINCETON, N.J., Jan. 26, 2012 /PRNewswire/ -- Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that it has recently received approximately $574,000, net of transaction costs, in non-dilutive...

WARSAW, Ind., Jan. 26, 2012 /PRNewswire/ -- Net Sales of $1.17 billion for the fourth quarter increased by 2.9% reported over the prior year period (2.4% constant currency)Diluted EPS for the fourth quarter were $0.87 reported, an increase of 383.3% over the prior year period, and $1.36...

BOULDER, Colo., Jan. 26, 2012 /PRNewswire/ -- Encision Inc. (ECIA:PK), a medical device company owning patented surgical technology that is emerging as a standard of care in minimally-invasive surgery, reported its financial results for its third fiscal quarter ended December 31,...

BETHLEHEM, Pa., Jan. 26, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) has scheduled its regular earnings conference call covering 2011 fourth quarter financial results and certain 2012 financial guidance for 5:00 pm ET (2:00 pm PT) on Wednesday, February 8, 2012. An update on certain business developments will also be provided.

Dutch-based biopharmaceutical company, Prosensa has raised €23m in new equity financing to advance its portfolio of RNA-modulating therapeutics for the treatment of rare diseases, including Duchenne muscular dystrophy (DMD), Myotonic Dystrophy (DM1) and Huntington's disease (HD).

Navidea Biopharmaceuticals has signed an option agreement with Alseres Pharmaceuticals to license [123I]-E-IAFCT Injection, developed as an aid in the diagnosis of Parkinson's disease and movement disorders.

Covance invests for growth as EPS drop 24% in Q4

Almirall, BioFocus enter three-year drug discovery alliance

Vaxiion Therapeutics, a biotechnology company, has received a new US patent related to minicell-based therapeutics.

Humira sales boost Abbott fourth-quarter figures again

Almirall, a pharmaceutical company, has entered into a three-year research alliance with BioFocus, an affiliate from Galapagos.

Spectrum Pharmaceuticals has signed an agreement to acquire licensing rights to market ZEVALIN (ibritumomab tiuxetan) injection for intravenous use outside of the US from Bayer Healthcare.

VANCOUVER, BRITISH COLUMBIA (MARKET WIRE) Pacgen Biopharmaceuticals Corporation ("Pacgen" or the "Company") (TSX VENTURE: PGA) announced today that it has closed its previously announced private placement (the "Private Placement") of 5,376,350 common shares to CurieMed Corporation. The common shares are issued at $0.0558 per common share, for aggregate subscription proceeds of $300,000.

AURORA, ON (MARKET WIRE) The Special Committee of the Board of Directors of Helix BioPharma Corp. (TSX: HBP) (NYSE Amex: HBP) (FRANKFURT: HBP) (the "Company" or "Helix") announces that Ernst & Young LLP ("Ernst & Young") has delivered its Interim Report. As announced on December 6, 2011, the Special Committee engaged Ernst & Young to assist the Special Committee in the investigation of the conduct of certain shareholders and parties related to these shareholders.

BEDFORD, Mass., Jan. 25, 2012 /PRNewswire/ -- Hologic, Inc. (NASDAQ: HOLX) today announced that company management will participate in the following investor conferences: Glenn Muir, Executive Vice President and Chief Financial Officer, will present at: The Leerink Swann...

DURHAM, NC (MARKET WIRE) Aldagen, Inc. today announced that a poster describing the homing properties of its cellular therapies was presented at the Seventh International Conference on Cell Therapy for Cardiovascular Disease. The data further explains the mechanism of action for Aldagen's cell therapy products, and supports the ability of these cells to home to the site of ischemic injury.

SUNNYVALE, Calif., Jan. 26, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today publication of a study demonstrating the benefits of the CyberKnife® Robotic Radiosurgery System in treating central lung...

PARSIPPANY, N.J., Jan. 26, 2012 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII) today announced that Nancy Lurker, the company's chief executive officer, is scheduled to present at the UBS 22nd Annual Global Healthcare Services Conference at 8:30 am ET on February 7, 2012 at The Grand...

[Business Wire] - Biogen Idec and Elan Corporation, plc today announced a global Phase 3b study, ASCEND, that is being conducted to evaluate the effectiveness of TYSABRI as a treatment for secondary-progressive multiple sclerosis .

MALVERN, Pa., Jan. 26, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that the first cohort of patients has been dosed in its phase Ib trial of XIAFLEX® (collagenase clostridium histolyticum) for the...

ROCKVILLE, Md., Jan. 26, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) announced today that tasimelteon was shown for the first time to reset the body clock and to align it to a constant 24-hour day in patients suffering from Non-24-Hour Sleep-Wake Disorder...

Boehringer Ingelheim announced the initiation of two phase III clinical trials...

QUEBEC CITY, Jan. 26, 2012 /PRNewswire/ - DiagnoCure, Inc. (TSX: CUR), a life sciences company that develops and commercializes high?value cancer diagnostic tests, today announced that its partner for the PrevistageTM GCC Colorectal Cancer Staging Test, Signal Genetics, reported...

Aphios has won a Phase II SBIR grant from the National Institutes of Health (NIH) amounting to $2.4m over two years.

Advaxis has announced the preliminary data from an ongoing randomized Phase 2 trial of ADXS-HPV with or without cisplatin in Indian women with recurrent/refractory cervical cancer.

CARMIEL, Israel, Jan. 26, 2012 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE Amex:PLX) (TASE:PLX), announced today that new clinical data on taliglucerase alfa will be presented at the 8th Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2012 being held February 8-10 in San Diego, California.

Marina Biotech has announced the initiation of Cohort 2 in dose escalation phase of the Safety and Tolerability of An RNAi Therapeutic in Familial Adenomatous Polyposis trial with CEQ508 shortly.

MOUNTAIN VIEW, Calif., Jan. 25, 2012 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) announced results of a clinical study evaluating the use of IRIDEX' MicroPulse laser therapy. The study examined the tissue-sparing therapy's effectiveness with patients diagnosed...

WOONSOCKET, R.I., Jan. 26, 2012 /PRNewswire/ -- With at least a dozen states reporting confirmed cases of pertussis (whooping cough) during the first three weeks of January, MinuteClinic, the largest provider of retail medical clinics in the United States, is urging...

TUCSON, AZ (MARKET WIRE) CDEX Inc. (OTCBB: CEXI), a leading developer of chemical detection products using patented technologies for use in healthcare, safety and security markets, today announced the appointment of Jason Bradley Terrell, M.D. as medical director of the company. Dr. Terrell will be responsible for CDEX's research and development, as well as regulatory and medical affairs related to the launch and ongoing development of the Valimed G4 drug validation system.

PRINCETON, N.J., Jan. 26, 2012 /PRNewswire/ -- BullMarket.com (http://www.bullmarket.com) ("BMR"), an online investment newsletter focused on long-term growth and income-generating stocks, has provided subscribers with coverage of several small-cap med-tech stocks, including Align...

TUCSON, AZ (MARKET WIRE) SynCardia Systems, Inc. (www.syncardia.com), manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that it has been nominated for one of the most prestigious awards in the European medical device industry.

FORT WORTH, Texas, Jan. 26, 2012 /PRNewswire/ -- Healthpoint Biotherapeutics today advised that the Centers for Medicare and Medicaid Services (CMS) has eliminated the physician 90-day global surgical period for the application of all skin and dermal substitutes, including OASIS®...

BOSTON, MA (MARKET WIRE) Pharmaceutical and biopharmaceutical companies, under pressure to increase R&D productivity, are expanding their use of strategic partnerships to bring new drugs to market more quickly and at lower cost, according to a panel of leaders from the research-based drug industry recently convened by the Tufts Center for the Study of Drug Development.

CHARLOTTE, N.C., Jan. 26, 2012 (GLOBE NEWSWIRE) -- Patients with Parkinson's disease, multiple system atrophy (MSA) and other neurological disorders can be greatly affected by the symptoms of their disease such as neurogenic orthostatic hypotension (NOH) that result from autonomic dysfunction. To give a voice to patients and their family caregivers who are impacted by the symptoms of NOH, Chelsea Therapeutics (Nasdaq:CHTP) announced today the formation of a partnership with leading medical and patient experts called the Alliance for NOH Awareness and the launch of an educational web site, www.SignsofNOH.com.

HOLLYWOOD, Calif., Jan. 26, 2012 /PRNewswire/ -- Medbox, Inc. (Pinksheets: MDBX) (www.medboxinc.com) announced today their new lineup of products for 2012. Through their subsidiary, Prescription Vending Machines, Inc., the company sells medicine dispensing and storage systems,...

MOBILE, Ala., Jan. 26, 2012 /PRNewswire/ -- HASCO Medical, Inc. (OTCBB: HASC), a managed healthcare provider that serves patients in Alabama, Florida, and Mississippi, is please to announce that the Company has launched its new web site,...

EAST HANOVER, N.J., Jan. 26, 2012 /PRNewswire/ -- Unity Management Group, Inc. (OTC: UYMG) (or "the Company") is pleased to announce its wholly owned subsidiary Metropolitan Computing Corporation (or MCC) is opening 2012 with a great head start. MCC has received $50,000 in new, annual...

BOCA RATON, Fla., Jan. 26, 2012 /PRNewswire/ -- Coverall Health-Based Cleaning System®, a leading franchisor of commercial cleaning businesses, has appointed Laura J. Hendricks as its President and Chief Executive Officer. Hendricks has more than 25 years of leadership...

SOUTH SAN FRANCISCO, Calif., Jan. 26, 2012 /PRNewswire/ -- Janssen Alzheimer Immunotherapy, together with its collaborator on the Alzheimer's Immunotherapy Program (AIP), Pfizer Inc. (NYSE: PFE), and the Geoffrey Beene Gives Back® Alzheimer's Initiative today...

THOUSAND OAKS, Calif., and ROCKVILLE, Md., Jan. 26, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Micromet, Inc. (NASDAQ:MITI) today announced that the companies have entered into a definitive merger agreement under which Amgen will acquire Micromet, a biotechnology company...

WASHINGTON, Jan. 26, 2012 /PRNewswire/ -- Today Janssen Healthcare Innovation, a team within Janssen Research & Development, LLC., (Janssen), announced the Janssen Connected Care Challenge at the Health Care Innovations Summit in Washington, D.C. The Janssen Connected...

NEW YORK, Jan. 26, 2012 /PRNewswire/ -- The National Basketball Association (NBA), the Women's National Basketball Association (WNBA) and the NBA Development League (NBA D-League), in collaboration with the American Diabetes Association and Sanofi US, today tipped off the second year...

BOSTON, Jan. 26, 2012 /PRNewswire/ -- MedAptus® today announced that its Professional Intelligent Charge Capture solution has once again been named the Mobile Data Systems Category Leader by KLAS. MedAptus' top-ranking score in the "2011 Best in KLAS Awards:...

CHARLOTTESVILLE, Va., Jan. 26, 2012 /PRNewswire/ -- ZyGEM Corp. Ltd., a developer and marketer of innovative products for the analysis of DNA and other nucleic acids, today announced that it has signed an OEM agreement with Saudi Diagnostics Limited (SDL) for ZyGEM's DNA and...

[Business Wire] - Celgene Corporation and Avila Therapeutics, Inc., a privately held biotechnology company developing targeted covalent drugs that treat diseases through protein silen

HAMM, Germany, January 26, 2012 /PRNewswire/ -- Ortho Caps GmbH today filed a notice of opposition to Align Technology's patent EP 2 263 599. With this filing, Ortho Caps has started the opposition procedure against the above patent in the European Patent Office (EPO). If successful, it...

PARK CITY, Utah, Jan. 26, 2012 /PRNewswire/ -- Nutraceutical International Corporation (NASDAQ: NUTR) today reported results for the fiscal 2012 first quarter ended December 31, 2011. Net sales for the fiscal 2012 first quarter were $46.6 million compared to $45.2 million for the...

MOUNTAIN VIEW, Calif., Jan. 26, 2012 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) today announced that the Company will present at the 9th Annual BIO Asia International Conference, January 31 -- February 1, 2012, in Osaka, Japan. The VIVUS presentation will take place on Tuesday, January 31, 2012 at 1:30PM JST at The Ritz-Carlton, Osaka.

NEW YORK, Jan. 26, 2012 /PRNewswire/ -- The third Aesthetic Plastic Surgery / Anti Aging Medicine: The Next Generation Symposium will be held on July 20-22, 2012 at the Conrad New York, a new luxury complex overlooking the Hudson River adjacent to One World Trade Center tower....

Syrris Custom Reactor Systems are ideally suited to processes requiring large reactor vessels...

CLARKSTON, Wash., Jan. 26, 2012 /PRNewswire/ -- Binaytara Foundation (BTF) and the University of Illinois Hospital and Health Sciences System have partnered with B.P. Koirala Memorial Cancer Hospital, Bharatpur, Nepal, in a project to develop the country's first Blood and Marrow Stem...

NEW YORK, Jan. 26, 2012 /PRNewswire/ --Reportlinker.com announces that a new market research report is available in its catalogue: Emerging Opportunities and Growth Prospects of Health and Wellness Tourism in...

AMPAC Fine Chemicals (AFC) has been granted Registration as a Manufacturer of Controlled Substances from the US Drug Enforcement Agency (DEA).

Zogenix and Battelle have announced an agreement to advance the development and commercialization of Zogenix's DosePro drug delivery technology outside Zogenix's core therapeutic focus areas.

Bill & Melinda Gates Foundation Announces $750 Million Contribution to the Global Fund, Affirming Support for the World's Largest Global Health Financier WASHINGTON, Jan. 26, 2012 /PRNewswire-USNewswire/ -- Today at the World Economic Forum in Davos, Switzerland, Gates...

NEW YORK (Reuters Health) - Robot-assisted surgery for prostate cancer has been heavily hyped, and a new study suggests that men's expectations of the surgery may be too high.

ZURICH (Reuters) - Patients with advanced colorectal cancer who received Roche's Avastin live longer when they also receive the drug as part of their second round of treatment, the Swiss drugmaker said on Thursday, citing a late-stage study.

Leo Pharma's Picato (ingenol mebutate) gel (0.015%, 0.05%) has gained US Food and Drug Administration (FDA) approval for the topical treatment of actinic keratosis (AK).

Vaxiion Therapeutics, a biotechnology company, has received a new US patent related to minicell-based therapeutics.

Leo Pharma's Picato (ingenol mebutate) gel (0.015%, 0.05%) has gained US Food and Drug Administration (FDA) approval for the topical treatment of actinic keratosis (AK).

The research conducted at the Leibniz Research Institute for Environmental Medicine (IUF) in Dusseldorf, Germany revealed that natural supplement Pycnogenol, an antioxidant was found to improve skin hydration and elasticity in women.

The work is published in this week's online Early Edition of the Proceedings of the National Academy of Sciences .

CHICAGO (Reuters) - After an exhaustive search, researchers at the Centers for Disease Control and Prevention have found no sign of an infectious agent, parasite or environmental exposure that could explain the mysterious skin condition known as Morgellons disease.

BATESVILLE, Ind., Jan. 25, 2012 /PRNewswire/ -- Hill-Rom Holdings, Inc. (NYSE: HRC) announced final financial results for its fiscal first quarter ended December 31, 2011 and reiterated its outlook for 2012. Earnings per diluted share decreased 4 percent during the period to $0.53 from...

Expert on pharmaceutics, chemistry, research familiar with Fort Worth FORT WORTH, Texas, Jan. 25, 2012 /PRNewswire-USNewswire/ -- UNT Health Science Center President Scott Ransom, DO, announced today the appointment of Myron (Mike) Jacobson, Ph.D., as the founding dean of the...

NEW YORK (Reuters Health) - Working out regularly may brighten the mood of people with chronic health problems like cancer, heart disease and back pain, according to the first sweeping look at previous research.

Device manufacturers are pushing the government and health insurers to cover weight-loss surgery, an effort that could give millions more obese Americans access to the treatments.

KENNESAW, Ga., Jan. 25, 2012 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that they will be...

CLEVELAND, Jan. 25, 2012 /PRNewswire/ -- DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced the newest member of its Connect Partner Program, Excel Life Sciences (ELS)....